Abstract
SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) are heavily altering the COVID-19 pandemic’s course due to their increased transmissibility, virulence and immune escape abilities. Data on their spread in western sub-Saharan Africa is however still scarce. We therefore sequenced viral genomes from SARS-CoV-2 cases identified in central and northern Côte d’Ivoire between May 2020 and March 2021. We report the introduction of VOC B.1.1.7 as early as mid-January 2021, followed by detection of a single case of VOC B.1.351, as well as VOI B.1.525. Since early 2021 VOC/VOI are gradually dominating the SARS-CoV-2 virus pool in Côte d’Ivoire, as seen in other regions of the world. Intriguingly, we also find that another lineage, A.27, has also been on the rise over the same period. In sum, this study highlights again the extremely rapid local diffusion of VOC, VOI and possibly A.27, and the importance of further reinforcing capacities for genomic surveillance on the African continent.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study is funded by two grants from the German Federal Ministry of Education and Research (BMBF; grant number 01KA1606; grant number 01KI2047). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study adheres to the tenets of the Declaration of Helsinki and national ethical and legislation standards. The CHU Bouaké laboratory is part of the national surveillance programme for SARS-CoV-2 diagnosis in Côte d'Ivoire. Approval by institutional ethics committees for conducting the ANDEMIA surveillance study was given by the Comité National d'Ethique des Sciences de la Vie et de la Santé de Côte d'Ivoire (ethics permit number 105/MSHP/CNER-dk), and by the Ethikkommission - Ethikausschuss am Campus Virchow-Klinikum, Charité, Germany (ethics permit number EA2/230/17). The study objectives were explained by trained surveillance officers, and informed written consent for participating in the study was collected from all participants. Written consent was obtained by parents or legal guardians of minors. Personal patient identifiers were not accessible to the authors. Inclusion of SARS-CoV-2 diagnostics into the study was granted by the Comité National d'Ethique des Sciences de la Vie et de la Santé de Côte d'Ivoire (ethics permit number 073-20/MSHP/CNESVS-kp).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
